Key result
PGE2 reversed iloprost-induced inhibition of platelet aggregation via the EP3 receptor, but added to inhibition by DN9693 or forskolin via the EP4 receptor.
Population
Platelet-rich plasma obtained from healthy volunteers
Comparison
Prostaglandin E2 with EP3 receptor antagonist or… vs PGE2 without EP receptor antagonists
Design
Preclinical
Authors
Loading...
EP3 antagonists may mitigate PGE2 prothrombotic effects; animal platelet data leave open translation to human atherothrombosis.
The prothrombotic effect of PGE2 in the presence of prostacyclin is mediated by EP3 receptors, supporting the potential therapeutic use of EP3 antagonists for atherothrombosis.
Glenn et al. (2012) studied Healthy volunteers. PGE2 and EP receptor antagonists (DG-041 and ONO-AE3-208) was evaluated on Platelet aggregation and VASP phosphorylation. PGE2 reversed iloprost-induced inhibition of platelet aggregation via the EP3 receptor, but added to inhibition by DN9693 or forskolin via the EP4 receptor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: